The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 06, 2026
Snapshot (as of Sep 06, 2026): Takeda Pharmaceutical Company Limited (TAK) pays a $100.00 annual dividend, yielding 3.48% at $18.45/share. Next ex-dividend date 2026-03-31. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.48%
Annual Dividend: $100.00 per share
Payout Ratio: 175.3% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2026-03-31
Sector: Healthcare
Years of Dividend History: 19
Takeda Pharmaceutical Company Limited dividend comes from one of the world's oldest pharmaceutical companies, founded in 1781 and now operating across oncology, rare diseases, gastroenterology, and plasma-derived therapies. TAK currently yields 3.48%, with trailing annual payments of $1.00 per share over the past twelve months. The next ex-dividend date is March 31, 2026. With a beta of 0.088, TAK stock moves very little relative to the broader market, which appeals to income-focused investors who prioritize low volatility over growth.
Takeda Pharmaceutical Company Limited pays out 175.3% of earnings as dividends, a payout ratio classified as high (above 75%). That figure means TAK is paying out more than it earns, which raises real questions about Takeda Pharmaceutical Company Limited dividend safety over time. The company's portfolio spans essential therapeutic areas, including treatments for rare diseases and digestive disorders under brands like Entyvio and Gattex, but a payout ratio this far above 100% leaves little room for earnings shortfalls without pressuring the dividend.
Takeda Pharmaceutical Company Limited dividend history shows a CAGR of -3.2% per year from 2009 to 2025. Per-share payments have fallen from $0.9996 to $0.5981 over that period (2026 data is partial and excluded from this calculation). The dividend peaked at $1.1098 in 2012 and has trended lower since, with the largest single-year gain in the window reaching 13.5% in 2011. Growth is negative. For income investors expecting rising payments over time, that is a meaningful drawback.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | -3.2% | $0.66 (2022) | $0.60 (2025) |
| 5-Year | -6.8% | $0.85 (2020) | $0.60 (2025) |
| 10-Year | -2.0% | $0.73 (2015) | $0.60 (2025) |
TAK fits income-focused investors who want low market sensitivity and can accept a dividend that has been shrinking, not growing. The yield of 3.48% sits in the moderate (2-4%) range, slightly below the 5-year average of 3.59%, which points to a yield that has not expanded meaningfully. The payout ratio of 175.3% is the central tension here: the yield is real today, but it is being funded at a level that exceeds reported earnings. What an investor gets is a low-beta healthcare stock with a meaningful current yield. What they accept is a dividend that has declined at -3.2% annually over sixteen years and carries a payout ratio that leaves no buffer.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-31 | $0.3083 |
| 2025-09-30 | $0.3221 |
| 2025-03-31 | $0.2760 |
| 2024-09-30 | $0.3261 |
| 2024-03-27 | $0.2922 |
| 2023-09-28 | $0.3191 |
| 2023-03-30 | $0.3100 |
| 2022-09-29 | $0.3296 |
| 2022-03-30 | $0.3301 |
| 2021-09-29 | $0.3969 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.3083 |
| 2025 | $0.5981 |
| 2024 | $0.6183 |
| 2023 | $0.6291 |
| 2022 | $0.6597 |
Project income from TAK with the TAK dividend calculator or track your full portfolio with the dividend tracker.